Stock Track | PEGBIO CO-B Soars 18.91% Intraday as Cornerstone Investors Extend Lock-Up Period, Signaling Strong Confidence

Stock Track05-05

PEGBIO CO-B's stock price surged 18.91% during intraday trading on Tuesday, marking a significant upward movement for the pharmaceutical company.

The sharp rise follows the company's announcement that its cornerstone investors have voluntarily agreed to extend their lock-up period. These investors will not reduce their holdings from the original expiration date until a later date, a move the company states reflects their strong confidence in PEGBIO's future prospects. This confidence is reportedly based on the firm's capabilities in advancing technological research and development and achieving important clinical milestones.

Analysts have highlighted PEGBIO as one of the few domestic enterprises with the capability to independently produce pharmaceutical-grade polyethylene glycol raw materials and integrate them throughout the drug development process for chronic diseases. The company has built a diversified product pipeline by focusing on innovative molecular entities, which combines clinical value with patient benefits.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143666529?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 16:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143666529","market":"nz","top_or_hot":-1,"title":"Stock Track | PEGBIO CO-B Soars 18.91% Intraday as Cornerstone Investors Extend Lock-Up Period, Signaling Strong Confidence","media":"Stock Track","content":"<p>PEGBIO CO-B's stock price surged 18.91% during intraday trading on Tuesday, marking a significant upward movement for the pharmaceutical company.</p><p>The sharp rise follows the company's announcement that its cornerstone investors have voluntarily agreed to extend their lock-up period. These investors will not reduce their holdings from the original expiration date until a later date, a move the company states reflects their strong confidence in PEGBIO's future prospects. This confidence is reportedly based on the firm's capabilities in advancing technological research and development and achieving important clinical milestones.</p><p>Analysts have highlighted PEGBIO as one of the few domestic enterprises with the capability to independently produce pharmaceutical-grade polyethylene glycol raw materials and integrate them throughout the drug development process for chronic diseases. The company has built a diversified product pipeline by focusing on innovative molecular entities, which combines clinical value with patient benefits.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PEGBIO CO-B Soars 18.91% Intraday as Cornerstone Investors Extend Lock-Up Period, Signaling Strong Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PEGBIO CO-B Soars 18.91% Intraday as Cornerstone Investors Extend Lock-Up Period, Signaling Strong Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-05 16:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PEGBIO CO-B's stock price surged 18.91% during intraday trading on Tuesday, marking a significant upward movement for the pharmaceutical company.</p><p>The sharp rise follows the company's announcement that its cornerstone investors have voluntarily agreed to extend their lock-up period. These investors will not reduce their holdings from the original expiration date until a later date, a move the company states reflects their strong confidence in PEGBIO's future prospects. This confidence is reportedly based on the firm's capabilities in advancing technological research and development and achieving important clinical milestones.</p><p>Analysts have highlighted PEGBIO as one of the few domestic enterprises with the capability to independently produce pharmaceutical-grade polyethylene glycol raw materials and integrate them throughout the drug development process for chronic diseases. The company has built a diversified product pipeline by focusing on innovative molecular entities, which combines clinical value with patient benefits.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1143666529","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143666529","pubTimestamp":1777969049,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PEGBIO CO-B's stock price surged 18.91% during intraday trading on Tuesday, marking a significant upward movement for the pharmaceutical company.The sharp rise follows the company's announcement that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"个股追踪|PEGBIO CO-B盘中大涨18.91%，因基石投资者延长禁售期，暗示信心强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PEGBIO CO-B's stock price surged 18.91% during intraday trading on Tuesday, marking a significant upward movement for the pharmaceutical company.The sharp rise follows the company's announcement that its cornerstone investors have voluntarily agreed to extend their lock-up period. These investors will not reduce their holdings from the original expiration date until a later date, a move the company states reflects their strong confidence in PEGBIO's future prospects. This confidence is reportedly based on the firm's capabilities in advancing technological research and development and achieving important clinical milestones.Analysts have highlighted PEGBIO as one of the few domestic enterprises with the capability to independently produce pharmaceutical-grade polyethylene glycol raw materials and integrate them throughout the drug development process for chronic diseases. The company has built a diversified product pipeline by focusing on innovative molecular entities, which combines clinical value with patient benefits.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143666529","isCrawlerRequest":true}